Total Payments
$11,050
2024 Payments
$650.49
Companies
29
Transactions
326
Medicare Patients
10,126
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$10,990 (99.5%)
Education$59.76 (0.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,990 | 316 | 99.5% |
| Education | $59.76 | 10 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,478 | 35 | $0 (2024) |
| PFIZER INC. | $1,411 | 30 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,220 | 30 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,092 | 30 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $946.55 | 43 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $911.03 | 27 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $795.82 | 25 | $0 (2023) |
| Merck Sharp & Dohme LLC | $574.31 | 17 | $0 (2024) |
| CVRx, Inc. | $474.00 | 5 | $0 (2023) |
| Amgen Inc. | $459.31 | 17 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $650.49 | 21 | Boehringer Ingelheim Pharmaceuticals, Inc. ($256.91) |
| 2023 | $779.28 | 24 | Merck Sharp & Dohme LLC ($257.13) |
| 2022 | $1,577 | 46 | Boehringer Ingelheim Pharmaceuticals, Inc. ($273.59) |
| 2021 | $1,272 | 47 | Janssen Pharmaceuticals, Inc ($311.30) |
| 2020 | $427.96 | 18 | Bardy Diagnostics, Inc. ($101.54) |
| 2019 | $1,827 | 45 | Novartis Pharmaceuticals Corporation ($427.99) |
| 2018 | $2,194 | 64 | PFIZER INC. ($449.22) |
| 2017 | $2,322 | 61 | E.R. Squibb & Sons, L.L.C. ($474.50) |
All Payment Transactions
326 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: DIABETES | ||||||
| 11/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $30.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/12/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $26.68 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 11/08/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $40.46 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $29.03 | General |
| Category: DIABETES | ||||||
| 08/02/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $29.22 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/22/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.84 | General |
| 07/05/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $48.25 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 06/10/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $21.39 | General |
| 06/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: DIABETES | ||||||
| 05/07/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/30/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $26.29 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.38 | General |
| Category: DIABETES | ||||||
| 03/28/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.20 | General |
| Category: Cardiovascular | ||||||
| 03/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $121.61 | General |
| Category: DIABETES | ||||||
| 03/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Respiratory | ||||||
| 02/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $30.90 | General |
| Category: DIABETES | ||||||
| 01/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $21.73 | General |
| Category: Cardiovascular | ||||||
| 01/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/05/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $36.76 | General |
| Category: Cardiovascular | ||||||
| 11/16/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.89 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/26/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $23.37 | General |
| Category: Not Applicable | ||||||
| 10/24/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 2,616 | 4,812 | $1.4M | $388,924 |
| 2022 | 23 | 2,608 | 4,666 | $1.4M | $401,551 |
| 2021 | 21 | 2,480 | 4,623 | $1.2M | $349,612 |
| 2020 | 25 | 2,422 | 4,584 | $1.2M | $317,028 |
Total Patients
10,126
Total Services
18,685
Medicare Billing
$1.5M
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 320 | 805 | $201,250 | $84,127 | 41.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 264 | 266 | $232,810 | $47,679 | 20.5% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 45 | 45 | $68,000 | $36,385 | 53.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 248 | 377 | $65,975 | $29,200 | 44.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 72 | 250 | $93,750 | $27,158 | 29.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 177 | 183 | $68,750 | $24,958 | 36.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 335 | $92,125 | $24,204 | 26.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 101 | 114 | $57,000 | $17,880 | 31.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 26 | 79 | $37,350 | $15,543 | 41.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 398 | 1,089 | $217,800 | $13,592 | 6.2% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 77 | 77 | $46,200 | $9,530 | 20.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $20,500 | $7,772 | 37.9% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 78 | 79 | $39,500 | $6,154 | 15.6% |
| 93261 | Evaluation of implantable defibrillator system | Office | 2023 | 37 | 96 | $24,000 | $5,890 | 24.5% |
| 93040 | Electrocardiogram (ecg) 1 to 3 leads with review by physician | Office | 2023 | 294 | 445 | $22,250 | $5,427 | 24.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 31 | 48 | $16,800 | $5,049 | 30.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 42 | $18,900 | $5,023 | 26.6% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 73 | 163 | $20,375 | $4,861 | 23.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 55 | 56 | $11,200 | $4,025 | 35.9% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2023 | 21 | 44 | $10,100 | $4,024 | 39.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 59 | 60 | $4,525 | $2,159 | 47.7% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 11 | 11 | $14,250 | $2,127 | 14.9% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2023 | 15 | 15 | $3,750 | $1,962 | 52.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $5,225 | $1,491 | 28.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 18 | 26 | $5,200 | $1,256 | 24.1% |
About Dr. David Schifter, MD
Dr. David Schifter, MD is a Cardiovascular Disease healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174553937.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Schifter, MD has received a total of $11,050 in payments from pharmaceutical and medical device companies, with $650.49 received in 2024. These payments were reported across 326 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($10,990).
As a Medicare-enrolled provider, Schifter has provided services to 10,126 Medicare beneficiaries, totaling 18,685 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Brooklyn, NY
- Active Since 07/04/2006
- Last Updated 10/11/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174553937
Products in Payments
- ELIQUIS (Drug) $2,083
- ENTRESTO (Drug) $1,340
- JARDIANCE (Drug) $960.61
- XARELTO (Drug) $911.03
- FARXIGA (Drug) $656.72
- VERQUVO (Drug) $574.31
- PRALUENT (Drug) $477.86
- Barostim Neo System (Device) $474.00
- MULTAQ (Drug) $317.96
- CHANTIX (Drug) $299.92
- Corlanor (Drug) $290.04
- XIFAXAN (Drug) $268.33
- BRILINTA (Drug) $245.16
- Vascepa (Drug) $203.37
- Carnation Ambulatory Monitor (Device) $190.10
- Kerendia (Drug) $182.88
- Repatha (Biological) $169.27
- PRADAXA (Drug) $131.82
- RESONATE (Device) $118.85
- LEQVIO (Drug) $116.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Brooklyn
Dr. Felix Yang, M.d, M.D
Cardiovascular Disease — Payments: $599,451
Cardiovascular Disease $599,451
Ozgen Dogan, Md, MD
Cardiovascular Disease — Payments: $367,116
Cardiovascular Disease $367,116
Dr. Adam Budzikowski, M.d., Ph.d, M.D., PH.D
Cardiovascular Disease — Payments: $346,063
Cardiovascular Disease $346,063
Dr. Peter Rouvelas, M.d, M.D
Cardiovascular Disease — Payments: $339,378
Cardiovascular Disease $339,378
Dr. Ronald Wharton, M.d, M.D
Cardiovascular Disease — Payments: $298,083
Cardiovascular Disease $298,083
Dr. Sorin Brener, Md, MD
Cardiovascular Disease — Payments: $225,799
Cardiovascular Disease $225,799